Advertisement

Topics

Rexahn & BioSense Enter License Agreement

04:30 EDT 16 Apr 2019 | Contract Pharma

To advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China

Original Article: Rexahn & BioSense Enter License Agreement

NEXT ARTICLE

More From BioPortfolio on "Rexahn & BioSense Enter License Agreement"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...